Licensing agreement with the famous Max Planck Society, extends patent protection for clinical research and strengthens the development projects of Nelivabon and Cortibon
The Company has also established an office in the United States, continuing its global expansion strategy
MUNICH, Germany, Jan. 25, 2022 (GLOBE NEWSWIRE) — HMNC Brain Health (“HMNC” or the “Company”), a clinical-stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry, announced that it has expanded its international patent portfolio in the field of psychiatric therapy with two patent families claiming substances for the treatment of major depressive disorder related to the stress axis. These licensing agreements are part of a broader collaboration with the renowned Max-Planck-Society, including biomarker patent claims and therapeutic patent claims covering markets in Europe, the United States and now Asia, especially in Japan.
Using a more personalized approach to discovering new drugs in psychiatry, the two targeted stress hormone therapies are promising patent candidates – corticotropin-releasing hormone 1 (CRHR1) receptor antagonists and corticotropin-releasing hormone 1 (CRHR1) receptor antagonists. vasopressin 1B (V1BR). Since only a limited proportion of patients with stress-related depression have consistently elevated levels of CRH or vasopressin, by tailoring therapies based on an individual’s biosignature through this targeted approach, some patients may gain better control. triggers for the production of a stress hormone.
Benedikt von Braunmühl, CEO of HMNC Brain Health, said:
“This is another example of our successful scientific collaboration initiatives, based on more than 30 years of research on depression and anxiety disorders. By strengthening the strategic protection of the intellectual property of our assets, we are further developing our patent portfolio internationally, with newly signed licenses and the assistance of Dr. Christian Kilger, a patent attorney at CH KILGER in Berlin. Dr. Kilger has successfully led many companies through complex patent oppositions, patent litigation and IPOs in the international biotechnology arena and will help us realize the full therapeutic and commercial potential of our compounds and to scale them globally for patients in need as well as for our investors.
The first licensed patent granted Japanese patent JP 6309511 B2, a V1b antagonist – which is being developed at the company’s subsidiary Nelivabon Project for use in the treatment of patients with elevated arginine vasopressin levels (AVP).
The second family of patents relates to the proposed CRHR1 antagonist for use in the treatment of patients with corticotropin-releasing hormone (CRH) hyperactivity. Patent EP 2 841 068 B1 was granted in 2018 and will expire in 2033. The filing of a supplementary protection certificate could further extend the term of the patent. The Company also currently has patent applications pending in the United States and Japan. These therapeutic patent claims are in addition to two other patent families covering the response of patients with CRHR1 antagonists (proprietary biomarkers).
HMNC Brain Health Director of Clinical Development, Dr. Hans Eriksson, added, “Extensive patent protection helps us pursue the highest quality clinical research as we work to transform therapy for neuropsychiatric disorders. We will put all our efforts into developing these promising compounds into highly effective drugs and improving the lives of many patients with major depressive disorder.
Additionally, HMNC Brain Health announced that it has established an office in the United States as the next step in pursuing its international expansion strategy. This follows the recent appointment of Nir Naor, who is based in the US, as the new Chief Financial Officer of HMNC Brain Health.
“We are entering an important growth phase for the Company and establishing a presence in the United States is a key step in our strategy of operational expansion and engagement in global capital markets,” said Mr. von Braunmühl.
About HMNC Brain Health
HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharmaceutical company pioneering the development of personalized therapies powered by predictive companion diagnostics, leading to significantly shorter treatment times and higher remission rates. The company is developing a unique pipeline to target both major depressive disorder (MDD) and treatment-resistant depression (TRD). The company operates in the United States and Germany and is backed by a renowned global venture capital firm, several family offices and a strategic healthcare investor. The company is now entering the next stage of its development with a large-scale licensing and fundraising program.
About the Nelivabon Project
HMNC Brain Health’s Nelivabon project includes the Phase II-ready compound nelivaptan and a corresponding molecular diagnostic test targeting 30% of major depressive disorders (MDDs) linked to dysfunction in the human body’s stress system (HPA axis). The neuropeptide vasopressin coordinates hormonal and behavioral adaptation to stress. Repeated stressors cause elevated vasopressin activity in the brain, potentially leading to increased anxiety and a major depressive episode. BH-200 is a vasopressin V1b receptor antagonist believed to be able to treat this dysfunction. The clinical development is coupled with a predictive companion diagnostic, which identifies depressed patients with underlying HPA axis dysfunction. Once clinically validated in conjunction with its predictive companion diagnostics, the Nelivabon project could represent a highly effective treatment for patients with stress axis-related MDD. The project is entering a Phase II proof-of-concept study in 2022.
About the Cortibon project
Under the Cortibon project, HMNC Brain Health is developing compound E2009, a corticotropin-releasing hormone (CRH) receptor 1 antagonist, licensed from Eisai, as well as a companion diagnostic. The neuropeptide corticotropin-releasing hormone coordinates hormonal and behavioral adaptation to stress. In about a third of patients with depression, CRH is thought to be involved in the development of the disease. CRH antagonists therefore have the potential to improve depressive symptoms. So far, it has not been possible to identify patients in whom elevated CRH in the brain is the cause of depression. As a result, CRHR1 antagonists have not yet entered the market. HMNC Brain Health has developed and clinically validated a molecular laboratory test that selects the subset of depressed individuals with a disturbance in their stress axis system and thus indicates which patients with depression will respond well to a stress blocker. CRH and which ones won’t.
Alexander Schmidt (Europe)
+49 151 22 99 39 765
Anne Donohoe (USA)
Contact Investor (WE)